• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Tempus

GSK Launches Accelerated Clinical Trial with Tempus

by Jasmine Pennic 01/13/2022 Leave a Comment

Cedars-Sinai Cancer Launches ‘Molecular Twin’ Initiative to Advance Precision Cancer Treatment

What You Should Know: - Tempus and GlaxoSmithKline (GSK) announced an accelerated phase II study evaluating the efficacy and safety of niraparib, an oral, once daily PARP inhibitor, for patients with breast and pancreatic cancers. The study, titled “Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors” (the PAVO study, NCT05169437) is sponsored by Tempus and opened for enrollment on January 7, 2022. - This trial’s data-driven design and site selection
Read More

Cedars-Sinai Cancer Launches ‘Molecular Twin’ Initiative for Precision Cancer Treatment

by Jasmine Pennic 09/09/2021 Leave a Comment

Cedars-Sinai Cancer Launches ‘Molecular Twin’ Initiative to Advance Precision Cancer Treatment

What You Should Know: - Cedars-Sinai Cancer and Tempus, a provider of artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients' DNA, RNA, protein and other information to help identify the most effective approach to each individual's disease. - By creating these "molecular twins," scientists can genetically classify cancer genes and proteins of particular tumors
Read More

CancerIQ Raises $5M to Expand Genetic Cancer Risk Assessment Platform

by Fred Pennic 08/14/2020 Leave a Comment

CancerIQ Raises $5M to Expand Genetic Cancer Risk Assessment Platform

What You Should Know: - CancerIQ raises $5M in Series A funding led by HealthXVentures to accelerate the growth of its genetic cancer risk assessment platform to identify and manage patients at high risk of cancer. - CancerIQ’s technology enables hospitals to use genomics to personalize the prevention and early detection of cancer. - Two new hires recently joined CancerIQ’s newly formed Integrated Products team from Epic, with the goal of advancing CancerIQ’s integration with leading
Read More

Philips Launches Pre-Hospital Wireless Monitoring Solution for Emergency Medical Response

by Fred Pennic 07/29/2020 Leave a Comment

Philips Launches Pre-Hospital Wireless Monitoring Solution for Emergency Medical Response

What You Should Know: - Philips receives 510(k) clearance from the FDA for its pre-hospital wireless monitoring solution (Tempus LS- Manual), now offering its remote monitor and defibrillator solution (Tempus ALS) to EMS customers in the U.S. - Solution delivers real-time bidirectional data transfer for remote patient monitoring, giving EMS responders a new approach to pre-hospital care. Philips, today announced the launch of its remote monitoring and defibrillator solution
Read More

The Many Faces of AI in Clinical Trials

by Dr. Ulrik Kristensen, Senior Market Analyst at Signify Research 02/28/2020 Leave a Comment

The Many Faces of AI in Clinical Trials

AI is being applied in several aspects for the clinical trial process today. From analyzing real-world data and scientific information to providing improved patient stratification and predictive outcomes, and assisting with different aspects of clinical trial operations. Here are some of the technologies using AI and machine learning in the clinical trial space today, outlining how they fit within the clinical trial ecosystem and discuss the impact on future clinical trial designs. The
Read More

CVS Health Launches Transform Oncology Care Program, Partners with Tempus

by Jasmine Pennic 12/12/2019 Leave a Comment

CVS Health Launches Transform Oncology Care Program, Partners with Tempus

- CVS Health launches Transform Oncology Care, which includes a comprehensive, first-of-its-kind precision medicine approach to oncology management for payors in collaboration with Tempus.- Transform Oncology Care includes an innovative precision medicine strategy that increases access to broad-panel gene sequencing tests for patients diagnosed with certain advanced-stage cancers. - The program also uses CVS’ local footprint and unique assets to improve patient outcomes and lower costs every
Read More

CB Insights Unveils ‘Digital Health 150’ List of Startups Transforming Healthcare

by Fred Pennic 10/02/2019 Leave a Comment

CB Insights Unveils ‘Digital Health 150’ List of Startups Transforming Healthcare

- CB Insights unveils first-ever annual ‘Digital Health 150’ list of digital health startups working to transform the healthcare industry. - The Digital Health 150 companies span a wide spectrum of categories that involve all three key stakeholder groups for the healthcare industry — providers, payers, and patients. - A total of 17 companies on the list are unicorns (private companies valued at $1B+). Of these, 12 companies are US-based, 3 are based in China, 1 is based in France, and 1
Read More

Tempus, Leidos Biomedical Research Inc. Launch Effort to Enhance The Cancer Genome Atlas

by Jasmine Pennic 06/11/2019 Leave a Comment

Tempus, Leidos Biomedical Research Inc. Launch Effort to Enhance The Cancer Genome Atlas

Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale announced today that it was selected by Leidos Biomedical Research Inc. (Leidos Biomed) to abstract and structure follow-up clinical data for The Cancer Genome Atlas (TCGA) Project for submission to the National Cancer Institute’s Genomic Data Commons (GDC).The Cancer Genome Atlas (TCGA) Project BackgroundThere are 230 distinct investigators that contributed
Read More

Data-Driven Precision Medicine Startup Tempus Lands $200M to Expand Into New Therapeutic Areas

by Fred Pennic 05/30/2019 Leave a Comment

Data-Driven Precision Medicine Startup Tempus Lands $200M to Expand Into New Therapeutic Areas

Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an additional $200M financing at a value of $3.1 billion dollars. The investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, Revolution Growth, and funds and accounts managed by T. Rowe Price. With this latest round, the company has raised $520 million since its founding in September 2015.Founded in 2015, Tempus has the largest
Read More

Tempus, Vanderbilt-Ingram Cancer Center Collaborate on Personalized Cancer Initiative

by Fred Pennic 01/05/2018 Leave a Comment

Tempus, Vanderbilt-Ingram Cancer Center Collaborate on Personalized Cancer Initiative

Tempus, a Chicago-based technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Vanderbilt-Ingram Cancer Center (VICC) have announced a new collaboration to improve outcomes for cancer patients. As part of the initial research project, Tempus will use its Tempus O platform to ingest and structure clinical data from the cancer center’s electronic health record. Tempus also will provide next generation
Read More

  • Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |